Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 2/22/22 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022 2/1/22 Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases 1/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/10/22 Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy 1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference 12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development 11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments Pagination First page « first Previous page ‹ previous … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Next page next › Last page last » Displaying 101 - 110 of 812 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 2/22/22 Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022 2/1/22 Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases 1/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 1/10/22 Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy 1/6/22 Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference 12/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 11/17/21 Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development 11/17/21 Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors 11/3/21 Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments Pagination First page « first Previous page ‹ previous … Page 7 Page 8 Page 9 Page 10 Current page 11 Page 12 Page 13 Page 14 Page 15 … Next page next › Last page last » Displaying 101 - 110 of 812